Mylan Gears Up To Launch US Advair Rival This Month
Mylan has revealed that its Wixela Inhub US rival to GSK’s Advair Diskus will be on the market by the end of February, acting quickly after their recent FDA approval.
You may also be interested in...
Mylan has launched its Wixela Inhub rival to GSK’s Advair Diskus at a 70% discount to the brand price.
The latest drug development news and highlights from our US FDA Performance Tracker.
The FDA’s approval for Mylan’s Wixela Inhub generic rival to GSK’s Advair Diskus is likely to give the company around a year’s head-start on other US generics being developed by Sandoz and Hikma.